Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Allied Minds Plc LSE:ALM London Ordinary Share GB00BLRLH124 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.275 -1.46% 18.625 18.00 19.25 - 18,627 16:35:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 1.5 -16.2 -6.0 - 45

Allied Minds Share Discussion Threads

Showing 7276 to 7299 of 8000 messages
Chat Pages: Latest  296  295  294  293  292  291  290  289  288  287  286  285  Older
DateSubjectAuthorDiscuss
13/5/2021
08:18
"As ever, the Board is committed to an open dialogue with all shareholders and welcomes constructive engagement." Hmm. After first rubbishing the vote by saying it was all down to one institutional shareholder.
spectoacc
13/5/2021
05:02
https://www.thisismoney.co.uk/money/markets/article-9572361/Allied-Minds-hit-major-investor-revolt-chairmans-pay.html
kooba
12/5/2021
22:21
My thoughts exactly, kooba. Hope something positive comes out of this...Something needs to change...
backinblack80
12/5/2021
21:49
Interesting AGM result ...47% voted against the chairman ..and 37% voted against another director..quite extraordinary. Looks like Invesco must have supported the board seems their way however bad things get ! But rather difficult to see how these directors can really stay in post with such a vote against. Not voted out as such but surely a sufficient lack of support to be able to stay.
kooba
08/5/2021
11:10
I think patience will be rewarded and worth a punt at the current price
pedigree_scum
07/5/2021
10:19
Could this be a triple bottom? Time for this company to get its act together to unlock its value. I will be issuing a letter to directors shortly.
escapetohome
06/5/2021
08:21
Nice uptick, are things finally turning here?
escapetohome
28/4/2021
08:13
Very large and growing market . Eye drops could be very important market looking at current medications that are coming to end of patent life , players in the space like Roche could be interested in new approaches.https://www.globenewswire.com/news-release/2020/07/19/2064118/0/en/Global-Diabetic-Macular-Edema-Market-2020-Top-Countries-Current-Landscape-And-The-Way-Forwardlong-Lasting-VEGF-Blockers-Compounds-With-VEGF-Independent-Mechanism-And-Topical-And-Or.html
kooba
28/4/2021
07:56
More on the company before a 3 year gap in getting funding to progress.28 September 2017SciFluor announces positive top-line results of phase 1/2 study of SF0166 topical (eye drop) ophthalmic solution in Diabetic Macular Edema patientsDemonstrated safety with no drug-related serious adverse eventsGreater than 50% of treated patients experienced a decrease in retinal thicknessPreparation for phase 2 trials underwayBoston, MA (28 September 2017) - SciFluor Life Sciences, Inc. (SciFluor), a subsidiary of Allied Minds, today announced positive top-line results of a Phase 1/2 study of SF0166, the company's lead drug in development for the topical (eye drop) treatment of patients with diabetic macular edema (DME).The Phase 1/2 study assessed the safety and preliminary efficacy of SF0166 in 40 evaluable patients with DME who were randomized to one of two dose strengths (2.5% and 5.0% solutions) self-administered by patients as an eye drop twice-a-day for 28 days, with a 28 day follow-up period. Results from a trial of SF0166 in patients with Age-related Macular Degeneration (AMD) remain pending.The primary outcome measure of safety was achieved with no drug-related serious adverse events observed in the study throughout the 28-day course of treatment as well as during the 28-day follow-up period. Ocular adverse events were recorded in the treated eyes of 6 patients. All events were mild in severity, with one considered possibly drug-related.SF0166 demonstrated biological activity in both patient groups (2.5% and 5% solutions), with 53% of the evaluable patients demonstrating a reduction in retinal thickness (RT), and improvements in visual acuity were also recorded. Durability of RT response to the 28-day course of therapy was observed during the month after discontinuing treatment.There were no significant decreases in visual acuity in study eyes during treatment or follow-up and no patient required rescue treatment with an anti-VEGF injection during the treatment phase. Regular anti-VEGF injections to the eye represent current standard of care for DME (and AMD).Based on these outcomes, SciFluor has decided to proceed to phase 2 trials for SF0166."The safety and biological activity, clearly demonstrated in this first-in-patient study, supports continued clinical development of SF0166," said David Boyer, MD, Retina-Vitreous Associates Medical Group of Los Angeles. "DME is a devastating condition that often results in vision loss. A safe and effective eye drop treatment for patients living with DME would be a major advance in the fight against this debilitating disease. A potential eye-drop treatment for DME may not only increase compliance, but also allow the opportunity to prevent vision loss by treating earlier in the disease pathway.""We believe SF0166 represents an important breakthrough in the treatment of retinal disease given its unique mode of action and its administration as an eye drop" said Omar Amirana, MD, SciFluor's Chief Executive Officer and Senior Vice President at Allied Minds. "We look forward to further advancing SF0166. We would like to thank the patients who participated in this study and the investigators and study staff who share our commitment to advancing the treatment of DME."Jill Smith, CEO of Allied Minds, commented "These results provide strong validation of the pre-clinical work undertaken at SciFluor with regard to SF0166, and a clear case for proceeding to phase 2 trials, for which SciFluor is now preparing. Results for wet-AMD phase 1/2 trials are due later this year. SF0166 is targeting a very large and growing market, with existing injectable drugs for DME and wet-AMD generating combined annual revenues exceeding $8 billion."ENDS
kooba
28/4/2021
07:47
I didn't know Allied Minds did slightly unexpected good news..but there you go.. got this in at nothing and their fully diluted post raise holding of 21.9% worth $6.5m ..a couple of p per share in assets. Long way to go to get through Phase 2 but where there's funding there's hope !! Not sure how involved AM has been in this raise and I note they are not supporting with new funds so presume they have not been the driving force.
kooba
26/4/2021
17:36
A little bit of movement here today, which was s very pleasing to see. Gives credence to my double bottom recent call.
escapetohome
23/4/2021
14:52
Orbital sidekick unfortunately a smaller interest i got a very good feeling..building out the ghost satellite constellation , fully funded. Revs for '21 mid single digits , revs '22 double digits and on to high double digits '23. Keen market in Us oil and gas lined up ..multiple other applications and possible global roll out.Decent upside on current recently raised valuation and once constellation up and running possible early exit opp i reckon..get the satellites up.
kooba
23/4/2021
14:45
All companies have merit and if they all hit projections then this time next year Rodney...But they kept saying there was virtually nothing they can do as not majority owners in forcing monetisation...so pretty much out of their hands if the strategic investors don't agree. And that it is too early to sell anything to obtain a realistic price. Be lucky in a fire sale to achieve share price let alone NAV.Which leaves the fate of the company somewhat out of their hands and somewhere down the road.Federated..so current Q $2.6M if i heard right looking at $17m for the year but and a big but i heard a run rate of $40m by end of the year. So instead of revenue of $40m for 2022 one should be looking far higher..even if the rate of revenue growth slowed you could be looking at $60-$80m for 2022..now this could truly be quite a different proposition if they achieve this as with that growth in a hot market a 8-10 times revenue multiple could figure on exit .If they hit these targets.Thing that worries is they massively missed last year ..but the ceo said covid was a positive for the connectivity industry ..so maybe referring to the covid thaw and that from here on its all sunshine but doesnt totally explain last year which was meant to be the big leap forward ..and wasn't.Should be a clearer picture middle of the year but could be decent upside on current value ..if they dont get diluted badly in likely late '21 early '22 funding round.
kooba
23/4/2021
14:30
Nice time to buy , hopefully double bottom.
escapetohome
23/4/2021
14:26
Now watched the whole CMD presentation.
kooba
23/4/2021
06:59
@kooba post #2473 - that sums it all up! Fair point that Invesco in particular have been a major block (as they are on everything, everywhere - often large holders who never support change).
spectoacc
22/4/2021
22:48
Both but very small in CA
buffettjnr
22/4/2021
22:15
Are you a shareholders in CA? Or AM ??
kooba
22/4/2021
20:54
Completely agree on both counts @flyfisher
buffettjnr
22/4/2021
20:43
Can see Lerdal joined spin , though Pignato still there , can see Rein on FW ..though Pignato still chair ? Cant see advisory boards on OS or Bridgecomm ..maybe me but seems Pignato still shows these directorships on LinkedIn. Is he representing AM ..I didn't think that was the idea??From the report and accounts showing Pignato was given almost $900k for loss of office but he was to be kept on in a temporary basis initially to 14th April 21 as CFO ..non board. Is he still there and what salary is he on ..still $500k ?? Is he or other AM directors taking personal directorship fees above and beyond their declared AM renumeration..difficult to tell. But maybe something that needs asking..current board structure does not seem aligned to shareholders interests.Note chair takes $164k in salary ..Must get me some NED roles!
kooba
22/4/2021
20:35
I am surprised any of you give credence to Crystal Amber, bernstein sold £5m of redde northgate last nov / dec at around 175 / 180, for a £9m loss. Redde has doubled since then. Just look at the dreadful performance of CRS and the charging structure. Both alm and crs need winding up.
flyfisher
22/4/2021
20:18
Think the problem is not CA as shareholder it has been Woodford and Invesco supporting a rubbish management and strategy hoping to protect their interests in AM investments...basically conflicted ..now there's so little left maybe not worth protecting anymore! Remember CA wanted wholesale change years ago and were not backed by those shareholders...might have been a different story if they had. Time for real change and focus on delivering value for shareholders not insiders.
kooba
22/4/2021
20:10
It worked pretty well with Leaf Clean Energy where CA held (i was small shareholder too) they brought in Mark Lerdal to head it up. The shares were almost worthless but It ended up being a legal case..Mark Lerdal took on large US corporate in US court and won..so did shareholders big time. He can walk the walk in the US and if CA wanted him to head it up then the track record is damn good.
kooba
22/4/2021
19:59
Brilliant if they get Lerdal in as Chairman but that entire CRS statement says as much about CRS as it does about ALM I fear. A comedy of errors, all of which were pointed out on this BB at the time, but also a continuation of years of similar errors out of ALM. CRS aren't a new shareholder, they've been major owners (& pumpers, via their reports) all this time, with their man Lerdal in for over a year (albeit as a non-exec). Hope for shareholders' sakes that CRS really do take hold of ALM now, and hope that when they do, there's plenty there to be recovered. Currently unclear where the next good news comes from.
spectoacc
Chat Pages: Latest  296  295  294  293  292  291  290  289  288  287  286  285  Older
ADVFN Advertorial
Your Recent History
LSE
ALM
Allied Min..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220705 03:13:24